Who Owns Onglyza?
Onglyza is owned by AstraZeneca, the British-Swedish pharmaceutical company listed on the London Stock Exchange and Nasdaq under ticker AZN. Onglyza is the brand name for saxagliptin, a DPP-4 inhibitor first approved by the FDA in July 2009. AstraZeneca acquired full rights from Bristol-Myers Squibb in 2014. The brand has been discontinued in the United States and withdrawn from European markets for commercial reasons as generic saxagliptin launched in 2023.
Parent Company
Acquired
2014
Status
Publicly Traded
Headquarters
Onglyza Timeline
GlobalOfficial Website
Who Owns Onglyza?
- Parent Company: AstraZeneca PLC
- Ownership Type: Product line
- Acquisition Year: 2014
- Company Type: Publicly Traded
- Stock Ticker: London Stock Exchange (also Nasdaq): AZN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Onglyza | AstraZeneca PLC | Product line |
Where to Buy
Disclosure: We may earn commission from purchases
Onglyza on AmazonAdvertisement
History of Onglyza
- Founded: 2009
- Founders: Bristol-Myers Squibb and AstraZeneca (joint development)
- Acquired by AstraZeneca PLC: 2014
Saxagliptin was developed within the Bristol-Myers Squibb and AstraZeneca diabetes alliance, which combined BMS's Amylin-derived diabetes science with AstraZeneca's commercial reach. The FDA approved Onglyza on July 31, 2009, as a once-daily DPP-4 inhibitor to improve glycemic control in adults with type 2 diabetes, and European approval followed under the same name.
The product entered the market behind Merck's Januvia and faced a significant setback in 2013-2014 when the SAVOR cardiovascular outcomes trial found saxagliptin associated with a small increased risk of hospitalization for heart failure. The FDA added a heart failure warning to the label in 2016, which weighed on the drug's competitive position.
Ownership consolidated under AstraZeneca in February 2014 when BMS exited diabetes to concentrate on oncology and immunology. The fixed-dose combination Komboglyze (saxagliptin plus metformin) and Kombiglyze XR extended the franchise modestly.
The brand's decline accelerated with US patent expiry. Generic saxagliptin from Aurobindo, Glenmark, and Mylan/Viatris launched on July 31, 2023. AstraZeneca subsequently marked both Onglyza strengths discontinued in the FDA's record, with a Federal Register determination that the withdrawal was not for safety or effectiveness reasons. European withdrawals followed, including Denmark's announcement that marketing of Onglyza would cease permanently from September 2025 for commercial reasons. By November 2026 the molecule lives on primarily as generic saxagliptin.
Advertisement
About AstraZeneca PLC
Is AstraZeneca a British or Swedish company?
AstraZeneca is a British-Swedish company. It was formed in 1999 by merging Sweden's Astra AB with the UK's Zeneca Group. Legally it is a UK public limited company headquartered in Cambridge, England, though it retains major operations in Sweden.
Is AstraZeneca publicly traded?
Yes. AstraZeneca PLC trades primarily on the London Stock Exchange under ticker AZN, where it is one of the largest FTSE 100 companies, and it maintains a secondary listing on Nasdaq under the same ticker.
When was AstraZeneca founded?
AstraZeneca was formed in 1999 through the Astra-Zeneca merger. Its roots extend to 1913, when Astra was founded in Sweden, and to Zeneca's 1993 spin-off from Imperial Chemical Industries.
Who leads AstraZeneca?
Pascal Soriot has been chief executive officer since 2012. He is credited with rebuilding the company's pipeline, rejecting Pfizer's 2014 takeover bid, and driving its current position as a top-tier oncology and rare disease company.
Advertisement
What is AstraZeneca's market position?
AstraZeneca is a top-10 global pharmaceutical company with $58.7 billion in 2025 revenue. It is a global leader in oncology and operates major franchises in CVRM, respiratory, and rare disease, with 16 blockbuster medicines and approximately 94,000 employees.
What are AstraZeneca's biggest products?
Tagrisso, Farxiga, Imfinzi, Lynparza, Soliris, Ultomiris, and Symbicort are among its largest products. Oncology alone generated $25.6 billion in 2025, and the company counts 16 medicines with annual sales above $1 billion.
- Founded: 1999
- Headquarters: Cambridge, England, United Kingdom
- Company Type: Publicly Traded
- Stock: London Stock Exchange (also Nasdaq): AZN
- Revenue: $58.74 billion total revenue (FY2025)
- Employees: Approximately 94,000
Where Is Onglyza Made / Based?
- Headquarters: Cambridge, England, United Kingdom
- Manufacturing / Operations: United States, Europe
Onglyza Categories & Tags
Brands Owned by AstraZeneca PLC
Healthcare PharmaceuticalsAstraZeneca
Owned by AstraZeneca PLC
British-Swedish pharmaceutical brand behind Tagrisso and Farxiga, owned by publicly traded AstraZeneca PLC formed by merger in 1999.
pharmaceuticalsprescription-drugsoncology
Healthcare PharmaceuticalsBydureon
Owned by AstraZeneca PLC
Exenatide extended-release weekly injectable for type 2 diabetes, owned by AstraZeneca since the 2012 Amylin Pharmaceuticals acquisition.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsFarxiga
Owned by AstraZeneca PLC
Dapagliflozin SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease, owned by AstraZeneca since its 2014 US launch.
pharmaceuticalsprescription-drugsdiabetes
Advertisement
Onglyza Ownership: Pros & Cons
Advantages
- +AstraZeneca ownership provided global regulatory and commercial infrastructure
- +2014 consolidation gave AZ full control of franchise economics
- +Combination products (Komboglyze) extended the molecule's reach
Considerations
- -SAVOR heart failure warning weakened competitive position from 2014
- -Lost out to Januvia within class and to SGLT2/GLP-1 drugs overall
- -Patent expiry triggered generic entry in July 2023
- -Brand discontinued in US and withdrawn in European markets
- -No meaningful ongoing revenue contribution to AstraZeneca
Frequently Asked Questions About Onglyza
Advertisement
Sources & Further Reading
Competitors to Onglyza
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Merck | USA | 2006 | Mass market | Global | All Genders | |
| Takeda | Japan | 2013 | Mass market | Global | All Genders | |
| Boehringer Ingelheim | Germany | 2011 | Mass market | Global | All Genders | |
| Bristol Myers Squibb | USA | 1994 | Mass market | Global | All Genders | |
| Sanofi | France | 2000 | Premium | Global | All-ages |
Learn More About Competitors
Healthcare PharmaceuticalsJanuvia
Owned by Merck & Co.
Prescription diabetes medication for treating type 2 diabetes by increasing insulin secretion, manufactured and marketed by Merck & Co.
diabetestype-2-diabetesdpp-4-inhibitor
Healthcare PharmaceuticalsNesina
Owned by Takeda Pharmaceutical Company
Alogliptin DPP-4 inhibitor for type 2 diabetes developed by Takeda Pharmaceutical, approved by the FDA in 2013 and now largely supplied by generic manufacturers.
diabetestype-2-diabetesdpp-4-inhibitor
Healthcare PharmaceuticalsTradjenta
Owned by Boehringer Ingelheim
Linagliptin DPP-4 inhibitor for type 2 diabetes, developed by Boehringer Ingelheim and co-marketed with Eli Lilly since its 2011 FDA approval.
diabetestype-2-diabetesdpp-4-inhibitor
Healthcare PharmaceuticalsMetformin
Owned by Bristol Myers Squibb Company
First-line biguanide medication for type 2 diabetes, originally marketed as Glucophage by Bristol-Myers Squibb and now one of the most widely prescribed generic drugs in the world.
diabetestype-2-diabetesbiguanide
Healthcare PharmaceuticalsLantus
Owned by Sanofi
Sanofi's long-acting insulin glargine for type 1 and type 2 diabetes, FDA approved April 2000, that reached peak global sales of $6.4 billion in 2015 before biosimilar competition eroded its market share.
diabetesinsulin-glarginetype-1-diabetes
Competitive Analysis
Market Positioning: Onglyza competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Onglyza
Looking for brands with different ownership structures? These similar brands are not owned by AstraZeneca PLC, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsTradjenta
Owned by Boehringer Ingelheim
Linagliptin DPP-4 inhibitor for type 2 diabetes, developed by Boehringer Ingelheim and co-marketed with Eli Lilly since its 2011 FDA approval.
diabetestype-2-diabetesdpp-4-inhibitor
Privately Owned
Tradjenta is privately owned, unlike Onglyza which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Privately Owned
Boehringer Ingelheim is privately owned, unlike Onglyza which is under a publicly traded parent company.
Healthcare PharmaceuticalsJardiance
Owned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
pharmaceuticalsprescription-drugsdiabetes
Privately Owned
Jardiance is privately owned, unlike Onglyza which is under a publicly traded parent company.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Onglyza which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Onglyza which is under a publicly traded parent company.
Healthcare PharmaceuticalsBenadryl
Owned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
antihistamineallergy-reliefcold-medicine
Privately Owned
Benadryl is privately owned, unlike Onglyza which is under a publicly traded parent company.
AstraZeneca PLC Stock Information
Advertisement
Jobs at AstraZeneca PLC
Latest News About Onglyza
Advertisement
Related Articles About Onglyza
View more articles
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
Health
Health Insurance Brand Ownership: The Big Players
UnitedHealth is #1 ($112B Q2 revenue, 26% MA share). CVS/Aetna is #3 ($106.1B Q2). Humana is #2 in MA (19.8%). Elevance is #2 by enrollment. Discover health insurance brand ownership. Explore our database.
Who Brands StaffNov 11, 2026
UnitedhealthAetnaCvs Health
Health
Organic Food Brand Ownership: Still Independent?
Annie's is General Mills ($820M). Cascadian Farm is General Mills (since 1999). Stonyfield is Lactalis (via Danone, $875M). Kashi is Kellogg's. Honest Tea was Coca-Cola (discontinued). Explore our database.
Who Brands StaffNov 9, 2026
Organic FoodAnniesCascadian Farm
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization